证券代码：600587 证券简称：新华医疗 公告编号：临 2024-035 山东新华医疗器械股份有限公司 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）子公 司上海天清生物材料有限公司于近日收到国家药品监督管理局颁发的《中华人民 共和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证的具体情况 1、产品名称：可吸收性外科缝线 2、注册证编号：国械注准 20243021789 3、注册人名称：上海天清生物材料有限公司 4、注册人住所：上海市松江区文翔路 419 号 5、生产地址：上海市松江区文翔路 419 号 6、结构及组成：可吸收外科缝线由缝线和缝合针（可选）组成，分带针型 （带单/双针）和不带针型。缝线经熔纺加工后表面切割出分布均匀的螺旋形单/ 双向倒刺。缝线材质：聚对二氧环己酮（PDO），单股、无涂层；缝合针材质： 302 不锈钢（化学牌号：12Cr18Ni9），含硅涂层；缝线染色：紫色，染料：D&C 紫色二号（CAS 号:81-48-1）。产品经环氧乙烷灭菌，一次性使用。 关于子公司产品获得三类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 ...

山东新华医疗器械股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 10 月 18 日(星期五) 上午 11:00-12:00 投资者可于 2024 年 10 月 11 日(星期五) 至 10 月 17 日(星期四)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 shinva@163. com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 证券代码：600587 证券简称：新华医疗 公告编号：临 2024-034 山东新华医疗器械股份有限公司（以下简称"公司"）已于 2024 年 8 月 30 日发布公司 2024 年半年度报告，为便于广大投资者更全面深入地了解公司 2024 年半年度经营成果、财务状况，公司计划于 2024 年 10 月 18 日上午 11:00- 12:00 举行 2024 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互 ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2]. Core Insights - The company reported a revenue of 5.187 billion yuan for the first half of 2024, reflecting a year-over-year growth of 2.24%, and a net profit attributable to shareholders of 484 million yuan, up 5.57% year-over-year [2]. - The medical device business is under pressure, but profitability continues to improve, with a gross margin of 26.65% and a net profit margin of 9.60% for the first half of 2024 [2]. - The company is focusing on cost reduction and efficiency improvements, leading to a significant enhancement in profitability metrics [2]. Revenue and Profit Forecast - The company is projected to achieve total revenues of 10.802 billion yuan, 11.671 billion yuan, and 12.637 billion yuan for the years 2024, 2025, and 2026, respectively, with growth rates of 7.89%, 8.05%, and 8.27% [3][4]. - Net profit attributable to shareholders is expected to reach 783 million yuan, 940 million yuan, and 1.162 billion yuan for the same years, with growth rates of 19.72%, 20.08%, and 23.62% [3][4]. Financial Metrics - The report highlights a projected PE ratio of 12x for 2024, 10x for 2025, and 8x for 2026, indicating a favorable valuation compared to comparable companies in the medical device sector [3]. - The company’s gross margin is expected to improve gradually, reaching 28.82% by 2026 [4]. Business Segment Performance - The medical device segment generated revenue of 1.887 billion yuan in the first half of 2024, down 2.55% year-over-year, while the pharmaceutical equipment segment saw revenue of 1.092 billion yuan, up 4.38% year-over-year [2]. - The company is adapting to market conditions by focusing on consumables and small-scale sterilization products, which are expected to drive growth in the second half of the year [2].

证券代码：600587 证券简称：新华医疗 公告编号：临 2024-033 山东新华医疗器械股份有限公司 关于公司产品获得三类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）于近 日收到国家药品监督管理局颁发的《中华人民共和国医疗器械注册证》，具体情 况如下： 一、医疗器械注册证的具体情况 1、产品名称： X 射线计算机体层摄影设备 2、注册证编号：国械注准 20243061705 3、注册人名称：山东新华医疗器械股份有限公司 4、注册人住所：山东省淄博市高新技术产业开发区新华医疗科技园 5、生产地址：淄博高新区齐祥路 3588 号 6、结构及组成：该产品由扫描架、扫描床、控制台、电源柜和选配件组成， 其中扫描架包含高压发生器、X 射线管组件、探测器、准直器，控制台含主机和 显示器，选配件包括头部延长板和头托。 7、型号、规格：XHCT-16iM 8、适用范围：该产品用于常规临床 CT 检查，可为放射治疗计划提供图像数 据。 9、批准日期 ...

Investment Rating - The report maintains a "Recommended" investment rating for the company with a target price of 25 yuan, compared to the current price of 16.62 yuan [1]. Core Views - The medical device sector is experiencing temporary pressure, but the company has optimized its expense ratio, leading to an improvement in net profit margin [1]. - The company reported a revenue of 5.187 billion yuan (+2.24%) and a net profit of 484 million yuan (+5.57%) for the first half of 2024 [1]. - The decline in medical device revenue is attributed to compliance actions and delayed procurement needs from hospitals [1]. - The international contract amount for pharmaceutical equipment has seen rapid growth, with domestic revenue at 5.082 billion yuan (+2.20%) and overseas revenue at 105 million yuan (+4.15%) [1]. - The company's gross margin slightly decreased to 26.65%, with the medical device segment's gross margin increasing to 43.29% despite a revenue decline [1]. - The overall expense ratio has improved, with a sales expense ratio of 7.88% (-0.78 percentage points) and a management expense ratio of 3.81% (-0.90 percentage points) [1]. - The company expects a gradual recovery in bidding activities in the second half of the year, maintaining profit forecasts for 2024-2026 [1]. Financial Summary - For the first half of 2024, the company reported a gross margin of 26.65%, with the medical device segment's gross margin at 43.29% and the pharmaceutical equipment segment's gross margin at 27.12% [1]. - The projected net profit for 2024-2026 is 830 million yuan, 1.04 billion yuan, and 1.28 billion yuan, respectively, with year-on-year growth rates of 27.3%, 24.7%, and 23.5% [2]. - The earnings per share (EPS) are expected to be 1.37 yuan, 1.71 yuan, and 2.11 yuan for 2024, 2025, and 2026, respectively, with corresponding price-to-earnings (PE) ratios of 12, 10, and 8 [2].

Investment Rating - The report maintains a "Buy" rating for Xinhua Medical [1] Core Views - In H1 2024, Xinhua Medical achieved operating revenue of 5.187 billion yuan (+2.24%) and a net profit attributable to shareholders of 484 million yuan (+5.57%), with a net profit margin of 9.6% (+0.19 percentage points) [1] - The company faced a decline in bidding for infection control products due to slow policy implementation, but expects recovery in H2 2024 as equipment update policies take effect [2] - The internationalization of pharmaceutical equipment is progressing, with significant growth in international trade contracts [2] - Cost control measures have significantly improved, with a reduction in sales and management expenses [2] Summary by Sections Financial Performance - In H1 2024, the company reported a revenue of 5.187 billion yuan, with a net profit of 484 million yuan and a non-recurring net profit of 474 million yuan [1] - For Q2 2024, revenue was 2.658 billion yuan (+0.91%) and net profit was 273 million yuan (+4.21%) [1] - The medical device segment generated revenue of 1.887 billion yuan (-2.55%) with a gross margin of 43.29% (+2.28 percentage points) [2] - The pharmaceutical equipment segment achieved revenue of 1.092 billion yuan (+4.38%) [2] Market Strategy - The company is focusing on major hospitals in the infection control sector and has achieved record high revenue in infection control consumables [2] - Continuous product upgrades and improvements in traditional surgical instruments have helped maintain market leadership [2] Cost Management - Sales expenses decreased by 6.94% to 409 million yuan, while management expenses fell by 17.41% to 198 million yuan [2] - R&D expenses increased by 3.75% to 18.53 million yuan, with several new products recognized for innovation [2] Profit Forecast - The report forecasts net profits of 818 million yuan, 950 million yuan, and 1.174 billion yuan for 2024, 2025, and 2026 respectively, with corresponding P/E ratios of 13, 11, and 9 times [2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The report highlights the company's focus on "medical devices + pharmaceutical equipment," improving operational structure and enhancing overall gross profit margin [1] - The company is expected to benefit from national policies supporting medical equipment updates, with an anticipated revenue increase from these initiatives [1] - The company has shown a commitment to cost control and profit expansion, aligning with ongoing state-owned enterprise reforms [1] Financial Performance Summary - For the first half of 2024, the company achieved operating revenue of 5.187 billion yuan, a year-on-year increase of 2.24%, and a net profit attributable to shareholders of 484 million yuan, up 5.57% [1] - The second quarter of 2024 saw operating revenue of 2.658 billion yuan, an increase of 0.91%, with a net profit of 273 million yuan, reflecting a growth of 4.21% [1] - The company’s net profit excluding non-recurring items reached 265 million yuan, marking a significant increase of 16.19% [1] Future Projections - The company is projected to achieve operating revenues of 11 billion yuan, 12 billion yuan, and 13 billion yuan for 2024, 2025, and 2026 respectively, with year-on-year growth rates of 9.5%, 9.2%, and 8.5% [2][3] - Net profit attributable to shareholders is expected to reach 831 million yuan, 1.053 billion yuan, and 1.267 billion yuan for the same years, with growth rates of 27.0%, 26.8%, and 20.2% respectively [2][3] - The report anticipates an increase in gross margin from 27.4% in 2023 to 31.0% by 2026 [5] Cost Management - The report notes a decrease in sales expenses by 6.94%, management expenses by 17.41%, and financial expenses by 13.00%, indicating effective cost control measures [1] - The company’s R&D expense ratio increased by 3.75%, reflecting a commitment to innovation while managing other costs effectively [1] Market Position and Strategy - The company is focusing on enhancing its core business in medical devices and pharmaceutical equipment, with a strategic emphasis on improving operational efficiency and risk management [1] - The report indicates that the company is well-positioned to capitalize on the growing demand for medical equipment due to government support and market trends [1]

1、产品名称：全自动糖化血红蛋白分析仪 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）于近 日收到山东省药品监督管理局颁发的《中华人民共和国医疗器械注册证》，具体 情况如下： 一、医疗器械注册证的具体情况 山东新华医疗器械股份有限公司 关于公司产品获得二类医疗器械注册证的公告 证券代码：600587 证券简称：新华医疗 公告编号：临 2024-032 2、注册证编号：鲁械注准 20242220826 3、注册人名称：山东新华医疗器械股份有限公司 4、注册人住所：山东省淄博市高新技术产业开发区新华医疗科技园 5、生产地址：淄博高新区齐祥路 3588 号 6、结构及组成：全自动糖化血红蛋白分析仪主要由进样系统、液相色谱分离 系统、比色检测与控制系统，显示打印系统，软件（软件类型：嵌入式，发布版 本：1.0）组成。 7、型号、规格：SGH-400。 8、适用范围：基于高效液相色谱法与新华医疗生产的糖化血红蛋白分析用洗 脱液（高效液相色谱法）和糖化血红蛋白溶血剂（高 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥5,186,552,479.09, representing a 2.24% increase compared to ¥5,072,990,454.71 in the same period last year[14]. - The net profit attributable to shareholders for the same period was ¥484,262,168.63, which is a 5.57% increase from ¥458,690,520.05 year-on-year[14]. - The net profit after deducting non-recurring gains and losses was ¥473,649,164.58, marking a significant increase of 15.11% compared to ¥411,475,879.82 in the previous year[14]. - Basic earnings per share for the first half of 2024 were ¥0.99, a decrease of 3.88% from ¥1.03 in the same period last year[15]. - The weighted average return on net assets was 6.50%, down by 0.36 percentage points from 6.86% in the previous year[15]. - The company reported a total of non-recurring gains of RMB 10,613,004.05, after accounting for tax and minority interests[17]. - The company achieved operating revenue of 518.66 million yuan, a 2.24% increase from 507.30 million yuan in the same period last year[26]. - Net profit attributable to shareholders reached 48.43 million yuan, up 5.57% from 45.87 million yuan year-on-year[26]. - The net profit excluding non-recurring gains and losses was 47.36 million yuan, reflecting a 15.11% increase from 41.15 million yuan in the previous year[26]. - The total comprehensive income for the first half of 2024 was CNY 498,122,236.45, compared to CNY 482,266,015.32 in the previous year, indicating an increase of 3.73%[91]. Cash Flow and Assets - The net cash flow from operating activities decreased by 54.57% to ¥137,257,876.10 from ¥302,139,384.60 in the same period last year[14]. - The total assets at the end of the reporting period were ¥15,552,985,032.22, showing a slight decrease of 0.24% compared to the previous year's total assets[14]. - The company reported a decrease in cash and cash equivalents by 9.20% to approximately ¥2.89 billion, down from ¥3.19 billion in the previous year[31]. - The company achieved a notable increase in accounts receivable, which rose by 15.00% to approximately ¥1.95 billion, compared to ¥1.69 billion in the previous year[31]. - The company's total liabilities decreased to ¥7,629,717,839.87 from ¥7,870,494,104.65[85]. - The company reported a short-term loan of ¥892,623,151.26, an increase from ¥851,947,102.23[84]. - The ending balance of cash and cash equivalents was CNY 2,748,646,264.75, an increase from CNY 2,435,195,899.61 at the end of the first half of 2023[95]. Market and Business Development - The medical device segment achieved record revenue in infection control consumables, with a historical high in sales during the reporting period[18]. - The pharmaceutical equipment segment saw a significant increase in international trade contracts, with new contracts for BFS equipment reaching a historical high[19]. - The company is focusing on automation, information technology, and internationalization in its product development strategy[19]. - The company is actively expanding its market presence through both online and offline sales channels, enhancing customer satisfaction and market influence[20]. - The company has successfully established an assembly plant in Indonesia and secured new collaborations with clients in Argentina, the Democratic Republic of the Congo, and Morocco[28]. - The company is pursuing international trade opportunities in laboratory equipment, establishing long-term strategic partnerships with distributors[19]. Research and Development - The company added 51 new authorized patents, including 8 invention patents, bringing the total to 3,590 authorized patents[27]. - The company has completed clinical trials for several diagnostic reagents, including the Longcheng Boxin anti-A and anti-B blood type reagents[19]. - Research and development expenses increased by 3.75% to approximately ¥185.27 million, up from ¥178.58 million in the previous year[30]. - The company’s R&D expenses include employee compensation, material costs, amortization and depreciation, travel expenses, technical service fees, and other related costs[172]. Environmental Responsibility - Environmental protection investment totaled CNY 1.1812 million in the first half of 2024, including CNY 0.156 million for air pollution control and CNY 0.456 million for wastewater treatment[48]. - The company has implemented various environmental protection measures, including radiation protection facilities costing CNY 0.4697 million[48]. - The company has not exceeded any pollutant discharge standards during the reporting period[45]. - The company has established an emergency response plan for environmental incidents, valid until June 6, 2025[50]. - The company is committed to environmental protection, implementing a management system compliant with GB/T24001-2016 standards[53]. Corporate Governance and Compliance - The company has not reported any significant risks that could materially affect its operations during the reporting period[3]. - The company has not reported any changes in the management team during the reporting period[42]. - The company maintains a good integrity status for both itself and its controlling shareholders during the reporting period[61]. - The company has not reported any violations or penalties against its directors, supervisors, or senior management during the reporting period[61]. - The company has committed to not utilizing its controlling influence to seek preferential treatment in business cooperation with related parties[60]. Legal Matters - The company reported a significant lawsuit involving 3M, with a claim amounting to RMB 6,000,000, which has been recognized as a contingent liability of RMB 1,985,000 for the fiscal year 2023[60]. - The company has ongoing litigation regarding patent infringement, with a court hearing scheduled for March 7, 2024, following a previous hearing on July 10, 2023[60]. - The company is actively involved in legal proceedings to protect its intellectual property rights, indicating a proactive approach to safeguarding its innovations[60]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 26,330[76]. - The company has completed the issuance of 140,004,597 shares through capital reserve conversion, increasing the total share capital to 606,686,586 shares[74]. - The top shareholder, Shandong Yiyang Health Industry Development Group Co., Ltd., holds 175,385,227 shares, representing 28.91% of total shares[77]. - The management team has seen an increase in shareholdings, with the chairman increasing his shares from 164,887 to 214,353, a change of 49,466 shares due to dividend distribution[81]. Future Outlook - Future outlook includes plans for market expansion and potential new product launches to drive revenue growth in the upcoming quarters[89]. - The company plans to implement a three-year dividend return plan from 2024 to 2026[40]. - The company is focused on energy conservation and emission reduction, promoting clean production in its operations[53].

证券代码：600587 证券简称：新华医疗 编号：临 2024-025 山东新华医疗器械股份有限公司 第十一届监事会第十二次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、 误导性陈述或者重大遗漏负连带责任。 一、监事会会议召开情况 山东新华医疗器械股份有限公司（以下简称公司）第十一届监事会第十二次 会议于 2024 年 8 月 16 日以通讯和书面方式发出通知，据此通知，会议于 2024 年 8 月 28 日在公司三楼会议室召开，应到监事 3 名，实到 3 名。会议由监事会 主席牟乐海先生召集和主持，符合《公司法》和《公司章程》规定。 二、监事会会议审议情况 （一）审议通过《公司 2024 年半年度报告全文及摘要》，并对公司 2024 年 半年度报告全文及摘要发表审核意见 公司监事会根据《证券法》、《公开发行证券的公司信息披露内容与格式准 则第 3 号—半年度报告的内容与格式（2021 年修订）》、《上海证券交易所股票上 市规则（2023 年 2 月修订）》、《上海证券交易所上市公司自律监管指南第 2 号— 业务办理》等与半年度报告编制有关的各项规定，对董事会编制的 2 ...